Key Highlights
- Oral semaglutide achieved its primary endpoint in a Phase 3 study involving young patients with type 2 diabetes
- Participants experienced a 0.83 percentage point greater reduction in HbA1c compared to placebo during a 26-week period
- Study enrolled 132 participants ranging from 10 to 17 years old
- If approved, this would mark the first oral GLP-1 medication authorized for pediatric populations
- The company intends to seek regulatory clearance in the United States and European Union during H2 2026
Thursday’s announcement from Novo Nordisk revealed promising outcomes from a Phase 3 clinical study demonstrating that oral semaglutide effectively reduces glycemic levels in young patients diagnosed with type 2 diabetes.
The study enrolled 132 participants aged between 10 and 17 years, monitored across a 26-week treatment period. Those receiving the active medication experienced HbA1c reductions 0.83 percentage points superior to participants given placebo.
According to the pharmaceutical company, these findings achieved statistical significance and fulfilled the study’s primary objective.
This marks a milestone as the inaugural clinical investigation of an oral GLP-1 medication in pediatric and adolescent populations. Presently, no oral GLP-1 treatment has received authorization for this demographic.
The medication currently reaches adult patients under the brand names Rybelsus and Ozempic pill. The Ozempic pill formulation is anticipated to launch in United States markets during Q2 2026.
Historically considered an adult metabolic disorder, type 2 diabetes increasingly affects younger populations. CDC statistics indicate approximately 364,000 youth under age 20 in the United States currently live with diagnosed diabetes.
Addressing Gaps in Pediatric Diabetes Management
Physicians managing younger diabetic patients face limited therapeutic choices. Metformin represents the standard initial therapy, yet approximately 50% of adolescent patients fail to achieve adequate glycemic control with this medication alone.
Insulin therapy remains another primary alternative, though it presents complications including hypoglycemic episodes and weight increase. An effective, well-tolerated oral medication would address a significant unmet medical need.
Martin Holst Lange, chief scientific officer at Novo Nordisk, noted the dramatic increase in type 2 diabetes prevalence among young individuals over recent decades.
“Oral semaglutide is an effective treatment option for children and adolescents with Type 2 diabetes who require glycaemic control beyond that provided by the current standard of care,” Lange said.
Company Plans Regulatory Submissions by Year’s End 2026
The Danish pharmaceutical manufacturer announced intentions to pursue label expansion approval for both Rybelsus and Ozempic pill to encompass pediatric and adolescent indications in American and European markets during the latter half of 2026.
Approval would establish semaglutide as the inaugural oral GLP-1 therapy authorized for younger patient populations.
Safety data from the trial aligned with findings observed across other semaglutide studies conducted in adult cohorts.
Successful regulatory clearance would broaden Novo’s semaglutide product portfolio into an untapped patient segment, potentially providing the Copenhagen-based company with competitive advantages over competitor Eli Lilly (LLY) within the diabetes and obesity treatment markets.
Novo Nordisk expects to complete regulatory submission processes in both jurisdictions prior to year-end.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
